Top-Down Drug Discovery™ is made possible by our data-immersive Avatar-Rx™ platform, which provides the ability to deep-mine fungal genomes for transformational precision medicines across different disease areas. This way, we're positioned to translate advancements in human genetics into the next wave of new medicines with unprecedented actionability, predictability and scalability. Learn more about Avatar-Rx™ and LifeMine's approach below and at www.LifemineTx.com
LifeMine Therapeutics
Biotechnology
Cambridge, MA 11,156 followers
LifeMine is a biopharmaceutical company pioneering Top-Down Drug Discovery™, a new approach that leverages evolution.
About us
LifeMine is a biopharmaceutical company pioneering Top-Down Drug Discovery™, a bold new approach that leverages evolutionary insights from fungi to unearth next-generation precision medicines. Through our data-immersive and technologically expansive discovery engine, we are uniquely positioned to bring mechanistically and structurally novel precision medicines to patients in urgent need of breakthrough disease intervention. LifeMine’s initial pipeline programs are focused in organ transplantation and antifungals. The Company is headquartered in Cambridge, MA, with offices in Gloucester, MA and Basel, Switzerland.
- Website
-
http://www.lifeminetx.com
External link for LifeMine Therapeutics
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Cambridge Discovery Park
30 Acorn Park Drive, 6th Floor
Cambridge, MA 02140, US
-
417 Main St., 2nd Floor
Gloucester, MA 01930, US
-
Basel, CH
Employees at LifeMine Therapeutics
Updates
-
LifeMine is making excellent progress as we seek to reimagine drug discovery and bring sophisticated, next-generation medicines to patients in urgent need. As we continue to evolve, we are thrilled to welcome Simon Cooper as our chief medical officer. Dr. Cooper brings an extensive background in translational medicine and clinical development, as well as a demonstrated track record working across multiple modalities in both pharmaceutical and biotech companies. He is exceptionally well-positioned to lead the continued advancement of our pipeline. We would also like to express our sincere gratitude to Elliot Ehrich, MD for his transformative contributions to LifeMine, especially his pivotal role in conceptualizing our CNi program and advancing our lead program LIFE-001. Dr. Ehrich will transition to the role of Clinical and Scientific Advisor. We are incredibly fortunate to have these two fantastic leaders on our team.
-
We are excited to share a recent publication in the Journal of Medicinal Chemistry that underscores the power of our data-immersive, genomics-enabled drug discovery engine of LifeMine. Through our Top-Down Drug Discovery™ approach, we have identified a novel family of enzyme-activated covalent CDK inhibitors. This represents the first example in which fungal genetically encoded molecules (GEMs) inhibiting a human protein of therapeutic interest were discovered first by a targeted search in genomic space. These molecules exhibit a remarkable and differentiated mechanism, forming a site-selective covalent bond to a specific CDK active site. This work truly highlights the ability of Top-Down Drug Discovery™ to identify mechanistically and structurally novel molecules for the development of new medicines. Congratulations to all our talented LifeMiners involved in this important work! Read more here in ACS Publications: https://lnkd.in/eYBdCd56
-
We are excited to announce that David Surguladze, MD, has joined LifeMine Therapeutics as Vice President, Head of Non-Clinical Development. With 27 years of distinguished experience in drug development, Dr. Surguladze will spearhead our preclinical development strategy, enhancing our efforts to deliver innovative medicines to patients in dire need of new treatments. We are confident in his expertise and leadership to guide our high-value pipeline projects towards success. Welcome to the team, David! We look forward to achieving remarkable milestones together in our journey to bring sophisticated medicines to patients in urgent need of breakthrough disease intervention.
-
This month, we come together to celebrate Pride and honor the diverse and vibrant LGBTQIA+ community within our workplace and beyond. At LifeMine, we believe in fostering an environment of belonging where everyone feels valued and respected. To celebrate Pride Month, we hosted a Paint & Sip event at our Cambridge location. It was a wonderful opportunity for LifeMiners to express their creativity and celebrate our commitment to diversity and inclusion. We're proud to support and stand with our LGBTQIA+ colleagues and friends, not just during Pride Month, but every day of the year. Together, we're building a workplace where everyone can thrive. Check out some of the amazing artwork from our Paint & Sip event below!
-
Top-Down Drug Discovery™ prioritizes a molecule’s function, versus its chemical structure, to identify pharmacologically privileged drugs to engage therapeutic targets in novel ways. LifeMine has the ability to significantly improve the speed of drug discovery comparable to the standard practice of “bottom-up” discovery which includes many complex, time-consuming steps, and is often labor and resource intensive, therefore unscalable to meet the demands of the future. We’re in uncharted territory, discovering and developing novel precision medicines against high-impact disease targets – including those previously deemed undruggable – with unprecedented speed, predictability, and scalability. Discover more from our Co-Founder and CEO, Greg Verdine, below.
-
“When do you ever see a fundamentally new way of discovering drugs? That’s what we’re dealing with." At LifeMine, we are the first company that was founded to discover powerful next-generation medicines that were evolved in nature, taking a bold new approach that leverages evolutionary insights from fungi to unearth sophisticated medicines for patients in urgent need of breakthrough disease intervention. This is the next wave of new medicines. This is Top-Down Drug Discovery™. This is LifeMine. Our Co-Founder and CEO, Greg Verdine, shares more below.
-
At LifeMine, recognizing Pride Month is about more than celebrating the LGBTQIA+ community; it’s about embracing diversity, promoting inclusion and belonging, and continuing to stand up for equality. Our Core DNA exemplifies our pursuit to learn through growth and curiosity within the lab and outside of it. By learning more about each other, we contribute to a more understanding and accepting culture for everyone. Happy #PrideMonth2024!
-
We’re thrilled to unveil our brand new look at lifeminetx.com. Our new website invites you into the world of LifeMine to explore our pioneering Top-Down Drug Discovery™ approach that leverages evolutionary insights from fungi to unearth next generation #precisionmedicines. Learn about our transformative platform, Avatar-Rx™, powerful programs and pipeline, and our remarkable team who embodies our expedition culture, driving our mission to bring sophisticated medicines to patients in urgent need. Check out the video below for a glimpse into our new virtual home, and visit our website to find out more.